Whereas most patients maintained humoral immunity throughout the observation period, we observed reduced cellular immune reactivity as measured by the ancestral-strain-stimulated ELISpot assay in a subset of patients. Half of the individuals (50%; 14/28) maintained cellular immunity three months after the fifth dose, despite acquiring humoral immunity.
19,310 Deaths · 91,037 Hospitalizations · 120,119 Urgent Care · 201,837 Doctor Office Visits · 2,556 Anaphylaxis · 6,415 Bell's Palsy · 2,075 Miscarriages · 9,555 Heart Attacks · 28,897 Myocarditis · 18,912 Permanently Disabled · 9,372 Thrombocytopenia · 15,537 Life Threatening · 37,007 Severe Allergic Reaction · 8,269 Shingles · 5,347 Myocarditis/Pericarditis · 3,742 Thrombocytopenia/Low Platelet ·
·
19,310 Deaths · 91,037 Hospitalizations · 120,119 Urgent Care · 201,837 Doctor Office Visits · 2,556 Anaphylaxis · 6,415 Bell's Palsy · 2,075 Miscarriages · 9,555 Heart Attacks · 28,897 Myocarditis · 18,912 Permanently Disabled · 9,372 Thrombocytopenia · 15,537 Life Threatening · 37,007 Severe Allergic Reaction · 8,269 Shingles · 5,347 Myocarditis/Pericarditis · 3,742 Thrombocytopenia/Low Platelet ·
·